The report notes EBITDA growth in line with estimates on gross margin expansion and reiterates ADD with a revised target price.
Read this note →Anthem Biosciences Limited
NSE ANTHEM BSE 544449 INE0CZ201020
0 filings · 0 analysed
958.15
+11.12%
over 1 month
-
HSIE Results Daily 05 Nov 26 HSIE
The report notes EBITDA growth in line with estimates on gross margin expansion and reiterates ADD with a revised target price.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 05 Nov 2026, 06:50 | long | 888.30 | 960.00 | 915.55 | 38% | open by 2027-11-05 |
| HDFC Securities | 07 Oct 2026, 15:25 | long | 887.05 | 950.00 | 915.55 | 45% | open by 2027-10-07 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report expects 23% YoY revenue growth led by the CRDMO business, naming it a strong performer.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief